Blog
RSS FeedPosted by Michael Wonder on 21 Mar 2022
CADTH releases its annual list of health technology trends to watch
18 March 2022 - New horizon scan report offers insights on health technology trends that have the potential to harness ...
Posted by Michael Wonder on 02 Mar 2022
Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the non-insured health benefits program for patients prescribed Ajovy (fremanezumab) for the preventive treatment of migraine in adults
2 March 2022 - Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada. ...
Posted by Michael Wonder on 02 Mar 2022
ALS Canada marks Rare Disease Day 2022 by calling on Ontario to champion expedited access to ALS therapies
28 February 2022 - The ALS Society of Canada Cana today marks Rare Disease Day 2022 by calling on the ...
Posted by Michael Wonder on 24 Feb 2022
AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba
24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...
Posted by Michael Wonder on 24 Feb 2022
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Ontario, Manitoba and New Brunswick
24 February 2022 - Private insurance coverage across Canada exceeds 90%. ...
Posted by Michael Wonder on 22 Feb 2022
New PMPRB report shows significant consistency in public drug plan coverage across Canada for drugs subject to "Common Drug Review" process
22 February 2022 - The Patented Medicine Prices Review Board released today the third and final part in the Alignment ...
Posted by Michael Wonder on 21 Feb 2022
Proposed PMPRB regulations requires focused dialogue with all players
16 February 2022 - Canada needs an approach that balances pricing considerations with the need to encourage investment, foster innovation, and ...
Posted by Michael Wonder on 21 Feb 2022
Drug funded for people with spinal muscular atrophy
15 February 2022 - The provincial government is covering costs for risdiplam, or Evrysdi, the medication used to treat a severe ...
Posted by Michael Wonder on 11 Feb 2022
AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients
10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...
Posted by Michael Wonder on 09 Feb 2022
Nova Scotia becomes fifth Canadian province to implement a biosimilar switching program
5 February 2022 - The province is the latest jurisdiction to adopt a program that will require patients to switch ...
Posted by Michael Wonder on 05 Feb 2022
CADTH establishes new post-market drug evaluation program
4 February 2022 - CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in ...
Posted by Michael Wonder on 30 Jan 2022
Baqsimi (nasal glucagon) rescue treatment for severe hypoglycaemia now covered in Ontario
28 January 2022 - Lilly Canada is pleased to announce that as of 31 January 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 13 Jan 2022
Quebec to impose health tax on unvaccinated Canadians
12 January 2022 - The Canadian province of Quebec will charge a health tax to residents who are not vaccinated ...
Posted by Michael Wonder on 15 Dec 2021
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia
15 December 2021 - Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. ...
Posted by Michael Wonder on 01 Dec 2021
Lilly Canada concludes successful negotiation with the Pan-Canadian Pharmaceutical Alliance for Baqsimi (glucagon nasal powder)
30 November 2021 - Lilly Canada is pleased to announce the completion of a successful negotiation with the pan-Canadian Pharmaceutical Alliance ...